What is the share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) today?
The share price of JAGSNPHARM as on 11th March 2025 is ₹208.18. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The past returns of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share are- Past 1 week: 6.53%
- Past 1 month: -13.13%
- Past 3 months: -23.28%
- Past 6 months: 24.81%
- Past 1 year: 72.25%
- Past 3 years: 110.50%
- Past 5 years: 2167.76%
What are the peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?
The peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) include:What is the dividend yield % of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The current dividend yield of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 0.94.What is the market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹1412.98 Cr as of 11th March 2025.What is the 52 week high and low of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The 52-week high of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹328.04 and the 52-week low is ₹109.44.What is the PE and PB ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) stock?
The P/E (price-to-earnings) ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 62.91. The P/B (price-to-book) ratio is 7.54.Which sector does Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belong to?
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares?
You can directly buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Jagsonpal Pharmaceuticals Ltd
JAGSNPHARMJagsonpal Pharmaceuticals Ltd
JAGSNPHARM


Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
27.01 | 7.54 | 0.94% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
46.89 | 5.97 | 0.56% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Jagsonpal Pharmaceuticals Limited is engaged in pharmaceutical business. It specializes in developing and manufacturing bulk drugs and pharmaceutical formulations.
Peers
Compare with peersGet more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 144.15 | 157.14 | 126.99 | 168.26 | 161.10 | 192.34 | 221.01 | 242.44 | 217.98 | 284.73 | ||||||||||
Raw Materials | 65.35 | 67.34 | 65.19 | 53.43 | 54.94 | 75.50 | 83.35 | 88.04 | 76.08 | 211.91 | ||||||||||
Power & Fuel Cost | 2.26 | 2.12 | 1.00 | 1.41 | 0.64 | 0.52 | 0.47 | 0.29 | 0.17 | |||||||||||
Employee Cost | 37.84 | 40.95 | 41.88 | 46.61 | 50.37 | 53.98 | 57.68 | 65.18 | 61.80 | |||||||||||
Selling & Administrative Expenses | 26.58 | 30.19 | 27.56 | 32.23 | 38.34 | 31.88 | 42.50 | 41.66 | 41.09 | |||||||||||
Operating & Other expenses | -0.34 | -2.50 | 2.01 | 23.81 | 5.75 | 6.99 | 8.56 | 10.85 | 6.50 | |||||||||||
EBITDA | 12.46 | 19.04 | -10.65 | 10.77 | 11.06 | 23.47 | 28.45 | 36.42 | 32.34 | 72.82 | ||||||||||
Depreciation/Amortization | 3.09 | 1.99 | 0.32 | 1.02 | 1.13 | 1.09 | 1.53 | 1.21 | 1.66 | 6.22 | ||||||||||
PBIT | 9.37 | 17.05 | -10.97 | 9.75 | 9.93 | 22.38 | 26.92 | 35.21 | 30.68 | 66.60 | ||||||||||
Interest & Other Items | 5.30 | 2.64 | 0.66 | 0.75 | 0.51 | 0.51 | 0.29 | 0.41 | 0.81 | 0.93 | ||||||||||
PBT | 4.07 | 14.41 | -11.63 | 9.00 | 9.42 | 21.87 | 26.63 | 34.80 | 29.87 | 65.67 | ||||||||||
Taxes & Other Items | 0.83 | 2.53 | -0.08 | 1.78 | 1.54 | 4.82 | 7.78 | 8.09 | 7.41 | 13.35 | ||||||||||
Net Income | 3.24 | 11.88 | -11.55 | 7.22 | 7.88 | 17.05 | 18.85 | 26.71 | 22.46 | 52.32 | ||||||||||
EPS | 0.49 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.41 | 7.92 | ||||||||||
DPS | 0.04 | 0.04 | 0.04 | 0.10 | 0.20 | 0.40 | 1.60 | 2.00 | 2.00 | 2.00 | ||||||||||
Payout ratio | 0.08 | 0.02 | — | 0.09 | 0.17 | 0.15 | 0.56 | 0.49 | 0.59 | 0.25 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Jagsonpal Pharmaceuticals Ltd | 62.91 | 7.54 | 0.94% |
Sun Pharmaceutical Industries Ltd | 40.38 | 5.76 | 0.84% |
Cipla Ltd | 28.66 | 4.41 | 0.89% |
Torrent Pharmaceuticals Ltd | 62.75 | 15.16 | 0.91% |
Price Comparison
Compare JAGSNPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
JAGSNPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.94%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.36 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 6, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateAug 21, 2023
Dividend/Share
₹5.00
Ex DateEx Date
Aug 21, 2023
Cash Dividend
Ex DateEx DateOct 29, 2021
Dividend/Share
₹4.00
Ex DateEx Date
Oct 29, 2021
Cash Dividend
Ex DateEx DateSep 22, 2021
Dividend/Share
₹1.00
Ex DateEx Date
Sep 22, 2021
Cash Dividend
Ex DateEx DateSep 22, 2020
Dividend/Share
₹0.50
Ex DateEx Date
Sep 22, 2020
Jagsonpal Pharmaceuticals has allotted 22,150 equity shares of Rs. 2/- each under JPL ESOP 2022, to the eligible employee of the Company, upon exercise of vested options. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,27,29,810 (constituting of 6,63,64,905 equity shares of Rs. 2/- each) to Rs. 13,27,74,112 (constituting of 6,63,87,056 equity shares of Rs. 2/- each).Powered by Capital Market - Live
Revenue from operations surged 56.7% to Rs 74.03 crore recorded in the quarter ended 31 December 2024. Profit before exceptional items and tax stood at Rs 15.48 in Q3 FY24, steeply higher than Rs 5.27 crore posted in Q3 FY23. The company reported an exceptional item of Rs 23.18 crore during the quarter. The company's operating EBITDA surged by 185% to Rs 171 crore in Q3 FY25, compared to Rs 60 crore recorded in the same quarter last year. The EBITDA margin also improved to 23.1% in Q3 FY25, up from 12.8% in Q3 FY24. On nine-month basis, the company's net profit climbed 158% to Rs 48.78 crore on 27.2% increase in revenue to Rs 210.16 crore in 9M FY25 over 9M FY24. The company reported a strong balance sheet, having concluded the sale of its Faridabad facility for Rs 41 crore, resulting in exceptional income during Q3 FY25. As of 31 December 2024, the company maintains a robust cash balance of Rs 132.1 crore. Regarding its successful acquisition integration, the company stated that the integration of the acquired business is progressing well. Q3 FY25 marks the second full quarter of operations, with performance aligning with expectations. Jagsonpal Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. Powered by Capital Market - Live
Net profit of Jagsonpal Pharmaceuticals rose 707.83% to Rs 31.99 crore in the quarter ended December 2024 as against Rs 3.96 crore during the previous quarter ended December 2023. Sales rose 56.74% to Rs 74.03 crore in the quarter ended December 2024 as against Rs 47.23 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales74.0347.23 57 OPM %21.387.18 - PBDT17.905.68 215 PBT15.495.27 194 NP31.993.96 708 Powered by Capital Market - Live
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 January 2025.Powered by Capital Market - Live
Jagsonpal Pharmaceuticals has fixed 08 January 2025 as record date for stock split of the Company such that 1 (one) equity share having face value of Rs. 5/- (Rupees five only) each, fully paid-up, be sub-divided into such number of equity shares having face value of Rs. 2 (Rupee two only) each, fully paid up. Powered by Capital Market - Live
Jagsonpal Pharmaceuticals has allotted 31,040 equity shares under ESOP. Consequently, the paid up equity share capital has increased to Rs. 13,27,29,810 (constituting of 2,65,45,962 equity shares of Rs. 5/- each). Powered by Capital Market - Live
Net profit of Jagsonpal Pharmaceuticals rose 53.41% to Rs 11.46 crore in the quarter ended September 2024 as against Rs 7.47 crore during the previous quarter ended September 2023. Sales rose 29.15% to Rs 74.69 crore in the quarter ended September 2024 as against Rs 57.83 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales74.6957.83 29 OPM %21.8114.47 - PBDT17.7110.42 70 PBT15.379.96 54 NP11.467.47 53 Powered by Capital Market - Live
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live
Net profit of Jagsonpal Pharmaceuticals declined 28.74% to Rs 5.33 crore in the quarter ended June 2024 as against Rs 7.48 crore during the previous quarter ended June 2023. Sales rose 2.14% to Rs 61.44 crore in the quarter ended June 2024 as against Rs 60.15 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales61.4460.15 2 OPM %16.6814.35 - PBDT11.4710.48 9 PBT10.4010.09 3 NP5.337.48 -29 Powered by Capital Market - Live
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 August 2024Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 5.31%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.08% to 0.06%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 25.48%, vs industry avg of 15.27%